Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Exclusion Criteria

• •Pregnant or lactating women
• •Any radiotherapy within 1 week of starting treatment on protocol.
• •Any major surgery within 1 weeks of starting treatment on protocol.
• •Any evidence of active clinically significant interstitial lung disease
• •A mean QTc \>470ms (Fridericia"s correction), clinically important arrhythmia, conduction or morphology of resting ECG (eg complete LBBB, 1st -3rd degree heart block, any factors that increase the risk of QTc prolongation or risk of arrhythmia)
• •Cardiovascular disease or cerebrovascular disease, CVA or MI \< 6 months prior to study enrollment, unstable angina, NYHA \>Grade II CHF, or serious cardiac arrhythmia uncontrolled by medication or with the potential to interfere with protocol treatment
• •History of pneumonitis or interstitial lung disease (ILD), drug induced ILD, radiation pneumonitits that required steroid treatment, and any evidence of clinically active ILD
• •Serious chronic GI conditions associated with diarrhea
• •Symptomatic, unstable brain metastases requiring escalating doses of steroids
• •Continue to have unresolved \> CTCAE grade 1 toxicity from any previous treatment